Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 9-11, 2006, Pages 1193-1196

  Calascibetta, A ^a   Cabibi, D ^a   Rausa, L ^a   Aragona, F ^a   Barresi, E ^a   Martorana, A ^a   Sanguedolce, R ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breast cancer; Proliferation index, Ki67; Thymidylate synthase

Indexed keywords

FLUOROURACIL; KI 67 ANTIGEN; THYMIDYLATE SYNTHASE;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL CYCLE PHASE; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MITOSIS; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; PROGNOSIS; THYMIDYLATE SYNTHASE;

EID: 33750470093     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600894527     Document Type: Article

References (9)

1. Keshgegian, A.A.; Cnaan, A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferation cell nuclear antigen, Ki 67 and Mib1. Am. J. Clin. Pathol. 1995, 104, 42-49.
2. Isola, J.J.; Helin, H.J.; Helle, M.J.; Kallioniemi, O.P. Evaluation of cell proliferation in breast carcinoma: comparison of Ki 67 immunohystochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990, 65, 1180-1184.
3. Nishimura, R.; Nagao, K.; Miyayama, H.; et al. Thymidylate syntahse levels as therapeutic and prognostic predictor in breast cancer. Anticancer. Res. 1999, 19, 5621-5626.
4. Kakimoto, M.; Uetake, H.; Osanai, T.; et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5 FU sensitivity by a histocultural drug sensitivity test. Cancer Lett. 2005, 223, 103-111.
5. Cabibi, D.; Calascibetta, A.; Campione, M.; Barresi, E.; Rausa, L.; Dardanoni, G.; Aragona, F.; Sanguedolce R. Clinical relevance of thymidylate synthase expression in the signet ring cell hystotype of colorectal carcinoma. Eur. J. Cancer 2004.
6. Foekens, J.A.; Romain, S.; Look, M.P.; Martin, P.M.; Klijn, J.G. Thymidine kinase and thimidylate synthase in advanced breast cancer: response to tamoxifene and chemotherapy. Cancer Res. 2001, 61, 1421-1425.
7. McGuire, W.L.; Clark, G.M. Prognostic factors and treatment decisions in axillary- node-negative breast cancer. N. Engl. J. Med. 1992, 326, 1756-1761.
8. Van Diest, P.J.; Baak, J.P.; Matze-Cok, P.; et al. Prediction of response to adjuvant chemotherapy in premenopausal lymph-node positive breast cancer patients with morphometry, DNA flow cytometry and Her-2/neu oncoprotein expression: Preliminary results. Pathol. Res. Pract. 1992, 188, 344-349.
9. Perrone, F.; Carlomagno, C.; Lauria, R.; De Lauentis, M.; Marabilo, A.; Panico, L.; Pettinato, G.; Petrella, G.; Gallo, C.; Bianco, A.R.; Di Placido, S. Selecting high risk early breast cancer patients: whath to add to the number of metastatic nodes? Eur. J. Cancer 1996.